Indications -- pain Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- pain

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: sim1	8/17/2010 9:35:58 AM
	of 101

FDA questions wider approval of Lilly's Cymbalta FDA questions whether Lilly's antidepressant Cymbalta is safe and effective for chronic pain On Tuesday August 17, 2010, 9:05 am WASHINGTON (AP) -- Federal health scientists are questioning whether the antidepressant Cymbalta is safe and effective enough to be approved for use against chronic pain. The Food and Drug Administration has posted its review of Eli Lilly and Co.'s application to market the drug for a range of pain ailments, including lower back pain. FDA reviewers have questions about the statistical methods used to study the drug and liver side effects. The blockbuster drug is already approved to treat depression, diabetic nerve pain and fibromyalgia. FDA reviewers note that an additional approval would greatly expand use of a drug already used by about 15 million patients. The FDA will ask a panel of outside experts to consider whether Cymbalta should be approved for chronic pain.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next